Skip to main content
Equibles

PRELUDE CAPITAL MANAGEMENT, LLC

Position in LPCN — Lipocine Inc.

CIK 1387508 NEW YORK, NY
Back to LPCN Full portfolio

Position in LPCN

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$100,913
+$100,913 QoQ
Shares Held
12,630
Ownership
0.153%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2020
2 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Derivatives in LPCN

reported options exposure · as of Sep 30, 2020
CallValue
$282
CallShares
12
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

PRELUDE CAPITAL MANAGEMENT, LLC holds $43,640,056 across 72 Biotechnology names.

# Ticker Company Shares Value (USD) Open
1 APGE
Apogee Therapeutics, Inc.
 58,590 $7,776,650
2 TECH
BIO-TECHNE Corp
 91,696 $6,478,322
3 PGEN
Precigen, Inc.
 882,267 $5,028,921
4 ROIV
Roivant Sciences Ltd.
 113,104 $4,002,750
5 RVMD
Revolution Medicines, Inc.
 10,997 $2,059,518
6 TWST
Twist Bioscience Corp
 18,976 $1,952,250
7 QURE
uniQure N.V.
 32,229 $1,484,467
8 MDXG
Mimedx Group, Inc.
 215,239 $828,670

All Filings in LPCN

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $100,913 12,630
2020-09-30 $282 200